Related references
Note: Only part of the references are listed.Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission
Masao Nawata et al.
Modern Rheumatology (2014)
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
Josef S. Smolen et al.
LANCET (2014)
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
MAINTENANCE OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW-MODERATE DISEASE ACTIVITY FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT: WEEK 52 RESULTS FROM THE CERTAIN STUDY
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Josef S. Smolen et al.
LANCET (2013)
Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis
Yoshiya Tanaka
CURRENT OPINION IN RHEUMATOLOGY (2012)
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
N. B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression
Silvia Bosello et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Association of Hepatocyte Growth Factor Promoter Polymorphism With Severity of Interstitial Lung Disease in Japanese Patients With Systemic Sclerosis
Kana Hoshino et al.
ARTHRITIS AND RHEUMATISM (2011)
High Incidence of NLRP3 Somatic Mosaicism in Patients With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome Results of an International Multicenter Collaborative Study
Naoko Tanaka et al.
ARTHRITIS AND RHEUMATISM (2011)
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial
J. Kekow et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
Benazir Saleem et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Two-Year Clinical and Radiographic Results With Combination Etanercept-Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2010)
Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis
Victoria Bejarano et al.
RHEUMATOLOGY (2010)
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis
S. M. van der Kooij et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment
D. Aletaha et al.
ARTHRITIS AND RHEUMATISM (2009)
The Good Initial Response to Therapy With a Combination of Traditional Disease-Modifying Antirheumatic Drugs Is Sustained Over Time The Eleven-Year Results of the Finnish Rheumatoid Arthritis Combination Therapy Trial
Vappu Rantalaiho et al.
ARTHRITIS AND RHEUMATISM (2009)
Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis
Olivier Brocq et al.
JOINT BONE SPINE (2009)
Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Paul Emery et al.
JOURNAL OF RHEUMATOLOGY (2009)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
A. E. van der Bijl et al.
ARTHRITIS AND RHEUMATISM (2007)
Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept
MH Buch et al.
ARTHRITIS AND RHEUMATISM (2005)
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis - Five-year experience from the FIN-RACo trial
K Puolakka et al.
ARTHRITIS AND RHEUMATISM (2005)
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal - Results from a twelve-month randomized, double-blind, placebo-controlled trial
MA Quinn et al.
ARTHRITIS AND RHEUMATISM (2005)
Share Paper
